Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy

Clinical trial NCT01548807 · COMPLETED

Trial details

NCT number

NCT01548807

Sponsor

Abramson Cancer Center at Penn Medicine

Status

COMPLETED

Phase

Phase 1

Study type

INTERVENTIONAL

Start date

2010-09-01

Primary completion

2017-01-04

Enrollment

19

View on ClinicalTrials.gov